Stay updated on Dupilumab in Chronic Urticaria Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in Chronic Urticaria Clinical Trial page.
Latest updates to the Dupilumab in Chronic Urticaria Clinical Trial page
- Check7 days agoChange DetectedAdded a dedicated Locations section listing Hesse, NRW, Rheinland-Pfalz, and Saxony as study sites; removed the previous state-specific location blocks.SummaryDifference0.5%
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the page. This appears to be a minor maintenance update that does not affect study data or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check35 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1. This update relates to page version metadata and does not modify study details, eligibility criteria, or outcomes.SummaryDifference0.1%
- Check43 days agoChange DetectedNotice about lapse in government funding and related operating status information was removed from the page.SummaryDifference0.4%
- Check57 days agoChange DetectedMinor layout and formatting changes observed on the Study Details page, with no changes to core study data (status, enrollment, endpoints, eligibility). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check86 days agoChange DetectedAdded a government funding status notice and updated the version to v3.2.0; removed the previous version tag v3.1.0.SummaryDifference4%
Stay in the know with updates to Dupilumab in Chronic Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in Chronic Urticaria Clinical Trial page.